Published in final edited form as:

Behav Brain Res. 2010 March 17; 208(1): 278. doi:10.1016/j.bbr.2009.11.036.

Increased Anxiety-Like Behavior of Rats During Amphetamine Withdrawal is Reversed by CRF-2 Receptor Antagonism

Shawn M. Vuong, Harvey A. Oliver, Jamie L. Scholl, Kathryn M. Oliver, and Gina L. Forster*
Neuroscience Group, Division of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota, 414 East Clark St, Vermillion, SD, USA

Abstract

Withdrawal from psychostimulants increases anxiety states, and amphetamine-treated rats show increased CRF₂ receptors in the serotonergic cell body region, the dorsal raphe nucleus (dRN). In the current study, amphetamine (2.5 mg/kg, ip, 14 days) pre-treated rats spent less time in open arms of the elevated plus maze compared saline pre-treated rats at both 24 hours or 2 weeks of withdrawal, and CRF₂ receptor antagonism (ASV-30; 2 µg/0.5 µl) within the dRN reversed the effects of amphetamine withdrawal on anxiety-like behavior. Overall, results suggest that CRF₂ receptor antagonism may be a novel pharmacological target for anxiety states during drug withdrawal.

Keywords

Psychostimulant; CRF₂ receptor; ASV-30; Elevated Plus Maze; Serotonin; Addiction

Transition from drug use to addiction may result, in part, from the need to alleviate dysphoric and anxiety states that emerge during drug abstinence [8]. In animal models, short-term (24-48 hours) withdrawal from cocaine increases anxiety-like behaviors [3,7,15,18] which are thought to drive drug craving and relapse [8,20]. However, an animal model of heightened anxiety states during protracted psychostimulant withdrawal has not been described, but is necessary to examine the neurobiology underlying anxiety during withdrawal.

Corticotropin-releasing factor (CRF) is released from the amygdala in response to stressors [12], and increases anxiety-like behaviors in rodents [11]. Likewise, psychostimulants activate CRF neurons [17], and alterations to CRF levels throughout the limbic system have been observed during psychostimulant withdrawal [19]. Alterations in CRF systems may represent a compensatory neuroadaptation to restore homeostatic function in response to the presence of the drug, but result in emotional dysfunction in the absence of the drug [8]. In support, intracerebroventricular (icv) administration of CRF antiserum or a CRF receptor antagonist reverses the heightened anxiety behavior observed at 48 hours after cocaine withdrawal in rats [3,18].

The serotonin (5-HT) neurons of the dorsal raphe nucleus (dRN) project throughout the limbic system and 5-HT is important in the regulation of anxiety states [13]. Both CRF₁ and CRF₂

*Address correspondence to: Gina L. Forster, Ph.D., Division of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota, 414 East Clark Street, Vermillion, SD 57069-2390, USA, gforster@usd.edu, Telephone: 605 677 6883, Fax: 605 377 6381.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

receptors are found in the dRN [4] and have opposing effects on 5-HT release [9]. Activation of CRF₂ receptors in the dRN increases 5-HT release in limbic brain regions [1,6,9]. Importantly, amphetamine treatment of rats daily for 14 days increased CRF₂ receptors in the dRN, which persisted for at least six weeks of withdrawal [16].

While activation of central CRF₁ receptors is associated with increased anxiety-like behavior in animal models, the exact role of CRF₂ receptors has not been clear [21]. Studies of CRF₂ knockout mice suggest that CRF₂ receptor activity may be associated with reduced anxiety-like behaviors [2]. However, icv administration of specific CRF₂ receptor agonists or antagonists increase or decrease rodent anxiety-like behaviors respectively, suggesting an anxiogenic effect of CRF₂ receptor activity [21]. Given that CRF₂ receptors are elevated in the dRN of amphetamine treated rats during protracted withdrawal [16], we hypothesized that amphetamine-treated rats would show heightened anxiety-like behavior during long-term withdrawal, and that administration of a specific CRF₂ receptor antagonist into the dRN would reverse this anxiety-like behavior.

Sixty-eight male Sprague-Dawley rats were acquired from the University of South Dakota Laboratory Animal Services (Vermillion, SD, USA) and housed in pairs at 22 °C (60% relative humidity) on reverse 12h light/dark cycle (dark cycle started at 10:00 am) with food and water freely accessible. The procedures were approved by the IACUC of the University of South Dakota, and were carried out in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Adult male rats were injected with amphetamine (2.5 mg/kg, ip) or saline daily within their holding room for 14 consecutive days [16]. Injections began one hour after the start of the dark cycle and rats were returned to their home cages following injections.

To determine whether increased anxiety-like behavior emerges immediately upon amphetamine withdrawal or during protracted withdrawal, rats were allocated to a 24 hour or 2 week withdrawal group (n = 10 per treatment group at each time period). The 24 hour period represents the shortest withdrawal period that can be easily distinguished and is the time point that reflects expectation of a subsequent injection. Rats were tested on the elevated plus maze (EPM) at 24 hours or two weeks after the last amphetamine or saline injection, and testing took place one hour after the onset of the dark phase of the light cycle in a dark room under red lighting. Each arm of the EPM was 50 cm × 11 cm, and the maze was elevated 1 meter from the ground with a camera positioned overhead (Noldus Information Technology, Wageningen, The Netherlands). Rats were introduced to the center of the EPM facing an open arm and allowed to explore the maze for 5 minutes. Latency to enter an open arm (sec), time spent on open arms (sec), and total distance traveled (cm) were measured by Ethovision 3.1. (Noldus Information Technologies).

To determine whether antagonism of CRF₂ receptors in the dRN could reverse increased anxiety-like behavior exhibited by amphetamine-treated rats in withdrawal, rats were tested for anxiety-like behavior 2 weeks following the last treatment. Seven days after last injection, saline and amphetamine treated rats (n = 14 per treatment group) underwent aseptic stereotaxic surgery for implantation of guide cannula into the dRN as described by [10]. Rats were anesthetized with a ketamine (80 mg/kg, ip.; Met-Vet, Libertyville, IL) xylazine (16mg/kg, ip.; Met-Vet) mixture and placed into a small mammal stereotaxic frame (David Kopf Institute, CA, USA). A 22-gauge, 5 mm long stainless steel guide cannula (Plastics One, Roanoke, VA) was stereotaxically implanted 1 mm above the dRN (AP: -7.8 mm from bregma, ML: -2.6 from midline; [14]) at a 23° lateral to medial angle, so to avoid the cerebral aqueduct and to ensure a bilateral infusion [10]. At the conclusion of surgery, the analgesic Ketoprofen (5 mg/kg, im.; Met-Vet) was administered. All rats were allowed three days of recovery before being acclimated to the dRN infusion procedure.

Following three days of acclimation to the infusion procedures as detailed by [10], rats were infused with either vehicle (2% ethanol) or the selective CRF₂ receptor antagonist antisauvagine-30 (ASV-30; 2 µg/0.5 µl; Sigma, [9]) using a 30-gauge stainless-steel infusion cannula (1 mm longer than the guide) inserted into the guide cannula. This vehicle has no effect on 5-HT release when infused into the dRN, and the dose of ASV-30 used is sufficient to completely block CRF₂ receptor-mediated effects in the dRN [6,9]. Furthermore, this volume infused into the dRN is thought to provide a specific bilateral effect, with little effective diffusion outside the dRN [5,10]. Twenty minutes after dRN infusion, rats were introduced to the EPM and behaviors measured as described above.

Rats were euthanized with Fatal Plus (0.5 ml, ip.; Vortech, Dearborn, MI, USA), brains were removed and fixed in 10% formalin. Brains were sectioned (60 µm) on frozen, stained with cresyl violet, and analyzed under light microscope by two experimenters blind to treatment. Only data from rats with cannulae placements in the dRN were included in the following data analyses (n = 7 amphetamine or saline pre-treated rats per dRN infusion group).

Behaviors were compared between saline and amphetamine pre-treatment groups at 24 hours and two weeks following the last treatment, or between pre-treatment groups that received vehicle or ASV-30 infusions, using separate two-way ANOVAs. Significant effects were analyzed further using Student-Newman-Keuls post-hoc test for multiple pair-wise comparisons. Significance levels for all statistical tests were set at $P \leq 0.05$ (SigmaStat v2.03, SPSS Inc., Point Richmond, CA, USA).

When anxiety-like behavior during amphetamine withdrawal was assessed, latency to enter open arms was significantly affected by pre-treatment treatment ($F_{1,33} = 8.338$, $P = 0.007$), but there was no effect of withdrawal period ($F_{1,33} = 0.173$, $P = 0.680$), nor an interaction between withdrawal period and pre-treatment ($F_{1,33} = 0.665$, $P = 0.421$). A significant increase in latency was observed between treatment groups only within the two week withdrawal group (SNK $P < 0.05$; Fig. 1A). Similarly, time spent in open arms was significantly different between pre-treatment groups ($F_{1,33} = 25.850$, $P < 0.001$) but was not affected by withdrawal period ($F_{1,33} = 0.0421$, $P = 0.839$), and an interaction between pre-treatment and withdrawal period was not observed ($F_{1,33} = 0.152$, $P = 0.699$). Time spent in the open arms was significantly decreased in the amphetamine treatment groups compared to saline treated rats within both the 24 hour and two week withdrawal periods (SNK $P < 0.05$; Fig. 1B). There was no effect of treatment ($F_{1,33} = 0.586$, $P = 0.449$), withdrawal ($F_{1,33} = 3.561$, $P = 0.068$), nor an interaction between treatment and withdrawal ($F_{1,33} = 0.362$, $P = 0.551$) on the total distance traveled in the maze (Fig. 1C).

For experiments that tested CRF₂ receptor mediation of amphetamine-induced anxiety-like behavior, placement of infusion cannulae into the dRN did not differ between saline and amphetamine pre-treated rats (Fig. 2A-B). A significant effect of pre-treatment ($F_{1,24} = 6.155$, $P = 0.021$), dRN infusion ($F_{1,24} = 5.900$, $P = 0.023$), and a significant interaction between pre-treatment and dRN infusion ($F_{1,24} = 4.916$, $P = 0.036$) was observed in the latency to enter open arms. Amphetamine pre-treated rats infused with vehicle showed greater latency to enter open arms compared with saline pre-treated rats and amphetamine pre-treated rats infused with ASV-30 (SNK $P < 0.05$; Fig. 2C). For time spent in open arms, there was an effect of dRN infusion ($F_{1,24} = 6.715$, $P = 0.016$) and an interaction between drug pre-treatment and dRN infusion ($F_{1,24} = 9.686$, $P = 0.005$). Amphetamine pre-treated rats infused with vehicle showed reduced time in open arms compared with saline pre-treated rats and amphetamine pre-treated rats infused with ASV-30 (SNK $P < 0.05$; Fig. 2D). There was no significant effect of pre-treatment ($F_{1,24} = 0.296$, $P = 0.592$), dRN infusion ($F_{1,24} = 0.00752$, $P = 0.932$), nor an interaction of pre-treatment and dRN infusion ($F_{1,24} = 0.0108$, $P = 0.918$) on total distance traveled in the maze (Fig. 2E).

Overall, our results show that rats exhibited heightened anxiety-like behaviors both 24 hours and two weeks following the last repeated injection of amphetamine. The distance traveled in the EPM was nearly identical between saline- and amphetamine-treated groups at both time points measured, suggesting that differences observed in anxiety-like measures were not due to differences in the activity between the treatment groups. Therefore, these findings suggest that chronic amphetamine treatment increases anxiety states, which persist during protracted drug withdrawal.

Infusion of a CRF₂ receptor antagonist directly into the dRN reduced anxiety-like behaviors exhibited by amphetamine pre-treated rats at two weeks of withdrawal, with no effect on locomotion within the maze. These results extend those of Pringle et al. [16] showing increased CRF₂ receptors in the dRN up to 6 weeks following 14 days of amphetamine treatment, and of Sarnyai et al. [18] and Basso et al. [3] demonstrating increased anxiety-like behaviors of rats at 48 hours of withdrawal following 14 days of cocaine treatment, which were ameliorated by icv CRF antiserum or a CRF_{1/2} receptor antagonist. Combined, these findings suggest that one of the mechanisms by which chronic psychostimulant treatment and withdrawal results in elevated anxiety states may be increased CRF₂ receptor activity in the dRN. Given that CRF₂ receptor activation within the dRN leads to increases in 5-HT release in limbic regions such as the amygdala and nucleus accumbens [1,9], heightened CRF₂ receptor activity in the dRN during amphetamine withdrawal may amplify serotonergic activity within the limbic system to result in increased anxiety states.

Interestingly, ASV-30 infusion in the dRN of saline pre-treated rats had no effect on anxiety-like behaviors. This result may be due to the saline pre-treated group exhibiting relatively low levels of anxiety-like behaviors (when compared to saline pre-treated rat of the first experiment that were not acclimated to handling prior to EPM testing). Our result is consistent with a number of studies showing that general CRF receptor antagonists administered intracranially or icv have little effect on the behavior of non-stressed animals (see [10]). However, in some studies, icv administration of ASV-30 decreases anxiety-like behavior of rats in the EPM without prior exposure to stress or drugs [21]. The discrepancy in findings may be due to the site of infusion, with CRF₂ receptor antagonism specific to the dRN only effective in rats that show heightened CRF₂ receptor levels in this region. This implies that chronic exposure to amphetamine results in dRN CRF₂ receptor regulation of behavior that is not typically mediated by the activity of these receptors in drug naive rats.

In summary, the current data suggest that chronic amphetamine treatment of rats results in an increased anxiety state which persists following drug abstinence, and that CRF₂ receptor antagonism within the dRN reverses this anxiety state. Future research should confirm these findings using different anxiety paradigms with more global antagonism of central CRF₂ receptors. Such future studies may suggest CRF₂ receptor antagonism as a possible direction for therapeutic treatment to reduce anxiety states during amphetamine withdrawal.

Acknowledgments

This work was supported by NIH grants COBRE P20 RR015567, which is designated a Center for Biomedical Research Excellence, and R01 DA019921 (to GLF), but is solely the responsibility of the authors and does not necessarily represent the official views of NIH. SMV was a Sanford School of Medicine Summer Medical Research Fellow. We thank Jeffrey Barr and Jessica Flanigan for assistance with behavioral experiments.

References

1. Amat J, Tamblyn JP, Paul ED, Bland ST, Amat P, Foster AC, Watkins LR, Maier SF. Microinjection of urocortin 2 into the dorsal raphe nucleus activates serotonergic neurons and increases extracellular serotonin in the basolateral amygdala. *Neuroscience* 2004;129:509–519. [PubMed: 15541873]

2. Bale TL. Sensitivity to stress: dysregulation of CRF pathways and disease development. *Horm Behav* 2005;48:1–10. [PubMed: 15919381]
3. Basso AM, Spina M, Rivier J, Vale W, Koob GF. Corticotropin-releasing factor antagonist attenuates the “anxiogenic-like” effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. *Psychopharmacology* 1999;145:21–30. [PubMed: 10445369]
4. Day HE, Greenwood BN, Hammack SE, Watkins LR, Fleshner M, Maier SF, Campeau S. Differential expression of 5HT-1A, alpha 1b adrenergic, CRF-R1, and CRF-R2 receptor mRNA in serotonergic, gamma-aminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus. *J Comp Neurol* 2004;474:364–378. [PubMed: 15174080]
5. Forster GL, Feng N, Watt MJ, Korzan WJ, Mouw NJ, Summers CH, Renner KJ. 2006 Corticotropin-releasing factor in the dorsal raphe elicits temporally distinct serotonergic responses in the limbic system in relation to fear behavior. *Neuroscience* 2006;141:1047–1055. [PubMed: 16713119]
6. Forster GL, Pringle RB, Mouw NJ, Vuong SM, Watt MJ, Burke AR, Lowry CA, Summers CH, Renner KJ. Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity. *Eur J Neurosci* 2008;28:299–310. [PubMed: 18702701]
7. Harris GC, Aston-Jones G. Beta-adrenergic antagonists attenuate withdrawal anxiety in cocaine- and morphine-dependent rats. *Psychopharmacology* 1993;113:131–136. [PubMed: 7862819]
8. Koob GF, Le Moal M. Addiction and the Brain Antireward System. *Annu Rev Psychol* 2008;59:29–53. [PubMed: 18154498]
9. Lukkes JL, Forster GL, Renner KJ, Summers CH. Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphe differentially affect serotonin release in the nucleus accumbens. *Eur J Pharmacol* 2008;578:185–193. [PubMed: 17945210]
10. Lukkes J, Vuong S, Scholl J, Oliver H, Forster G. Corticotropin-releasing factor receptor antagonism within the dorsal raphe nucleus reduces social anxiety-like behavior after early-life social isolation. *J Neurosci* 2009;29:9955–9960. [PubMed: 19675229]
11. Matsumoto Y, Abe M, Watanabe T, Adachi Y, Yano T, Takahashi H, Sugo T, Mori M, Kitada C, Kurokawa T, Fujino M. Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents. *Neurosci Lett* 2004;358:99–102. [PubMed: 15026158]
12. Merali Z, McIntosh J, Kent P, Michaud D, Anisman H. Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central nucleus of the amygdala. *J Neurosci* 1998;18:4758–4766. [PubMed: 9614249]
13. Millan MJ. The neurobiology and control of anxious states. *Prog Neurobiol* 2003;70:83–244. [PubMed: 12927745]
14. Paxinos, G.; Watson, C. *The Rat Brain in Stereotaxic Coordinates*. San Diego: Academic Press; 1998.
15. Perrine SA, Sheikh IS, Nwaneshiudu CA, Schroeder JA, Unterwald EM. Withdrawal from chronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety- and depression-like behaviors in the rat. *Neuropharmacology* 2008;54:355–364. [PubMed: 18045627]
16. Pringle RB, Mouw NJ, Lukkes JL, Forster GL. Amphetamine treatment increases corticotropin-releasing factor receptors in the dorsal raphe nucleus. *Neurosci Res* 2008;62:62–65. [PubMed: 18585412]
17. Rotllant D, Nadal R, Armario A. Differential effects of stress and amphetamine administration on Fos-like protein expression in corticotropin releasing factor-neurons of the rat brain. *Dev Neurobiol* 2007;67:702–714. [PubMed: 17443818]
18. Samyay Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G. Brain corticotropin-releasing factor mediates ‘anxiety-like’ behavior induced by cocaine withdrawal in rats. *Brain Res* 1995;675:89–97. [PubMed: 7796157]
19. Samyay Z, Shaham Y, Heinrichs SC. The role of corticotropin-releasing factor in drug addiction. *Pharmacol Rev* 2001;53:209–243. [PubMed: 11356984]
20. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. *Arch Gen Psychiatry* 2006;63:324–331. [PubMed: 16520439]
21. Takahashi LK. Role of CRF(1) and CRF(2) receptors in fear and anxiety. *Neurosci Biobehav Rev* 2001;25:627–636. [PubMed: 11801288]

Figure 1.

(**A**) Latency to enter open arms, (**B**) time spent in open arms and (**C**) total distance moved in the elevated plus maze for amphetamine and saline pre-treated rats at 24 hours and 2 weeks withdrawal. Data represent mean $\pm$ SEM. N = 10 per treatment at each time point. *Significant differences between saline and amphetamine pre-treated rats within the one time point.

Figure 2. Schematic representations (adapted from [14]) illustrating the location of dorsal raphe nucleus (dRN) infusions for (A) saline pre-treated and (B) amphetamine pre-treated rats. (C) Latency to enter open arms, (D) time spent in open arms and (E) total distance moved in the elevated plus maze for amphetamine and saline pre-treated rats infused with either vehicle or ASV-30 into the dRN. Data represent mean $\pm$ SEM. N = 7 per treatment group. *Significant differences between ASV-30 and vehicle within the same pre-treatment group. #Significant differences between saline and amphetamine pre-treated rats within the same dRN treatment group.